FDA Consulting Role Would Not Compromise Independence - Lumpkin
This article was originally published in The Tan Sheet
Executive Summary
FD's independence and objectivity would not be compromised by an expanded consulting role, FDA Deputy Director for Review Management Murray Lumpkin, MD, said at a Tufts Center for the Study of Drug Development meeting in Philadelphia Jan. 27.